About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingPhase 2NCT04856085

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy

Lead sponsor: Vir Biotechnology, Inc.•5 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Vir Biotechnology, Inc.

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Male or female ages 18 - \<66 years
•Chronic HBV infection for \>/= 6 months
•On NRTI therapy for \>/= 2 months at the time of screening

Exclusion Criteria

•Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation
•Significant fibrosis or cirrhosis
•History or evidence of drug or alcohol abuse
•History of chronic liver disease from any cause other than chronic HBV infection
•History of hepatic decompensation
•History of anaphylaxis
•History of allergic reactions, hypersensitivity, or intolerance to monoclonal antibodies, antibody fragments, or any excipients of VIR-3434
•History of immune complex disease
•History of known contraindication to any interferon product

Related studies

National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

NCT04166266 · Hepatitis D, Chronic, Hepatitis B, Chronic

Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion

NCT06550622 · Hepatitis B, Chronic

RECRUITINGEARLY Phase 1

Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B

NCT05922306 · Hepatitis B, Chronic

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

NCT05870969 · Carcinoma, Hepatocellular, Hepatitis C, Chronic, and more

Active Not RecruitingPhase 3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

NCT05630820 · Chronic Hepatitis B, Hepatitis B, Chronic

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 21, 2025Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE2

Enrollment244

Start dateJul 2021

Last updatedOct 21, 2025

Condition

Hepatitis B, Chronic

Locations shown

Investigative Site

San Francisco, California

Investigative Site

Miami, Florida

Investigative Site

Orlando, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 21, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions